Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 2/20 | 0.36 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.36 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.36 |
| ▸ | NEK1 | Q96PY6 | 2/20 | 0.36 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15001056 | 0.91 | IKBKB (0.36) | IKBKBPRKAG1PRKAA1NEK1PRKAB1 | |
| SCHEMBL14992844 | 0.91 | IKBKB (0.36) | IKBKBPRKAG1PRKAA1NEK1PRKAB1 | |
| SCHEMBL15001059 | 0.91 | IKBKB (0.36) | IKBKBPRKAG1PRKAA1NEK1PRKAB1 | |
| SCHEMBL427518 | 0.87 | IKBKB (0.37) | IKBKBPRKAG1PRKAA1NEK1PRKAB1 | |
| SCHEMBL427531 | 0.87 | IKBKB (0.37) | IKBKBPRKAG1PRKAA1NEK1PRKAB1 | |
| SCHEMBL427482 | 0.86 | IKBKB (0.39) | IKBKBPRKAG1PRKAA1NEK1PRKAB1 | |
| SCHEMBL427443 | 0.86 | IKBKB (0.40) | IKBKBPRKAG1PRKAA1NEK1PRKAB1 | |
| SCHEMBL15001068 | 0.84 | IKBKB (0.34) | IKBKBPRKAG1PRKAA1NEK1PRKAB1 | |
| SCHEMBL430745 | 0.84 | IKBKB (0.39) | IKBKBPRKAG1PRKAA1NEK1PRKAB1 | |
| SCHEMBL427477 | 0.84 | IKBKB (0.39) | IKBKBPRKAG1PRKAA1NEK1PRKAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2785181-B1 | 2-(SUBSTITUTED-PHENYL)-CYCLOPENTANE-1,3-DIONE COMPOUNDS, AND DERIVATIVES THEREOF | SYNGENTA LTD (GB) | 2016-08-17 | — | — | EP | disclosed |
| US-9107415-B2 | 2-(substituted-phenyl)-cyclopentane-1,3-dione compounds, and derivatives thereof | SYNGENTA PARTICPATIONS AG (CH) | 2015-08-18 | — | — | US | disclosed |
| US-20140323303-A1 | 2-(SUBSTITUTED-PHENYL)-CYCLOPENTANE-1,3-DIONE COMPOUNDS, AND DERIVATIVES THEREOF | SYNGENTA PARTICIPATIONS AG (CH) | 2014-10-30 | — | — | US | disclosed |
| EP-2785181-A1 | 2-(SUBSTITUTED-PHENYL)-CYCLOPENTANE-1,3-DIONE COMPOUNDS, AND DERIVATIVES THEREOF | Syngenta Limited (GB) | 2014-10-08 | — | — | EP | disclosed |
| WO-2013079708-A1 | 2-(SUBSTITUTED-PHENYL)-CYCLOPENTANE-1,3-DIONE COMPOUNDS, AND DERIVATIVES THEREOF | SYNGENTA LIMITED (GB) | 2013-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323303-A1 | 2-(SUBSTITUTED-PHENYL)-CYCLOPENTANE-1,3-DIONE COMPOUNDS, AND DERIVATIVES THEREOF | CNPY2, CBR3, CBR1 | IKBKB 4174/4885PRKAG1 3437/4885PRKAA1 3769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.